Each step. Every patient. Exactly what you need.

Personalize Colorectal Cancer Treatment with Myriad Oncology Tests

Revealing the full picture with germline and tumor genomic testing for colorectal cancer

Uncover hidden risks

1 in 5 have familiar clustering1

Don’t miss crucial information

Tumor testing alone can overlook up to 10% of key genetic variants2

Bridge the testing gap

Currently, only 6% of patients receive potentially life-saving genetic insights3,4

How would you approach Fiona’s germline and tumor genomic testing?

Based on national guidelines for cancer care,5,6,7 Fiona meets the criteria for combined germline and tumor genomic testing. These guidelines, established by leading oncology organizations, recommend comprehensive genetic profiling for patients like Fiona to inform treatment decisions and assess hereditary risk factors.

Infographic of the simplified approach to Myriad Oncology’s patient pathway showing the different Myriad Oncology tests available for high-risk unaffected, diagnosed, progression, and survivorship patient types.Infographic of the simplified approach to Myriad Oncology’s patient pathway showing the different Myriad Oncology tests available for high-risk unaffected, diagnosed, progression, and survivorship patient types.

Ongoing support for your practice to optimize the patient care you provide

Myriad’s industry-leading variant reclassification program ensures that each variant of uncertain significance (VUS) is continuously re-evaluated until a definitive classification is available.

Patient education

Pre- and post-test education as live, point-of-care sessions with a board-certified Genetic Counselor

Affordability

Transparent pricing with personalized cost estimates, financial assistance, and other affordability options, including direct pay

Faster results

Consolidated germline and tumor genomic results are available on average of 14 days after lab receives the sample

Uncover hidden
risks

1 in 5 have familiar clustering1

Provider support

Medical Science Liason’s support providers and their teams in answering clinical, testing, and results-related questions

Lifetime commitment

Myriad’s Variant Classification Program includes a Lifetime Reclassification Commitment to send amended reports if a variant of uncertain significance (VUS) is reclassified and is clinically actionable

MYRIAD ONCOLOGY

Each step. Every patient. Exactly what you need.

Get started with Myriad Oncology. Request more information from our team.

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.


Don't know your NPI? Click Here
Don't know your NPI? Click Here

By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon cancer V5.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 28, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615.
  3. Kurian AW, Abrahamse P, Furgal A, et al. Germline genetic testing after cancer diagnosis. JAMA. 2023;330(1):43-51.
  4. Schrock-Kelley S, Souter V, Hall MJ, et al. Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing. Commun Med. 2024;4:18.
  5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon cancer V5.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 28, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  6. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615.
  7. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022;40(11):1231-1258.